ER
EDIT icon

Enlightenment Research’s Editas Medicine EDIT Stock Holding History

Enlightenment Research’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,200
Closed -$214K – 153
2021
Q3 		$214K Buy
+5,200
New +$285K 0.26% 117

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Enlightenment Research's EDIT Position: Q4 2021 in Review

Enlightenment Research sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 5,200 shares — an estimated $214K sold.

Enlightenment Research first reported a position in EDIT in Q3 2021 and held it in 1 quarter. The position peaked at $214K in Q3 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Enlightenment Research reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Enlightenment Research sold 5,200 Editas Medicine shares in Q4 2021, an estimated $214K.
  • Enlightenment Research first reported a position in Editas Medicine in Q3 2021 and held it in 1 quarter.
  • Enlightenment Research's Editas Medicine position peaked at $214K in Q3 2021.
  • 305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Enlightenment Research's 13F filing for Q4 2021, filed 14 Feb 2022.